全球銅綠假單胞菌感染藥物市場2022-2029

市場動態

由銅綠假單胞菌引起的醫院感染增加

銅綠假單胞菌藥物市場增長的主要因素是銅綠假單胞菌引起的醫院感染增加、抗菌素耐藥性的快速增加以及治療銅綠假單胞菌的藥物研發的增加感染。

與銅綠假單胞菌相關的醫院感染率上升，如尿路感染 (UTI)、肺炎、囊性纖維化和血流感染，將在預測期內推動全球銅綠假單胞菌藥物市場的增長，預計將推動預計重症監護病房中銅綠假單胞菌感染率的上升將推動對新銅綠假單胞菌治療的需求。根據美國疾病控制和預防中心 (CDC) 的數據，美國每年發生大約 51,000 例與醫療保健相關的銅綠假單胞菌感染。其中，超過 6,000 種（13%）是多重耐藥菌，每年約有 400 人死於這些感染。已發現醫院獲得性感染 (HAI) 死亡率增加是由於銅綠假單胞菌所致，尤其是在免疫功能低下的患者中。大約 35% 的醫療相關感染會導致呼吸道、泌尿、胃腸道和其他疾病，導致對銅綠假單胞菌藥物的需求增加。

在治療銅綠假單胞菌感染中增加使用抗生素也促進了市場增長。由於越來越多地使用抗生素治療銅綠假單胞菌感染，耐抗生素細菌的出現使這種治療基本上無效。在這種情況下，製藥公司正專注於開發抗藥性細菌的治療方法。這為銅綠假單胞菌感染治療市場的參與者提供了充足的空白空間。

不斷增加的投資和廣泛的研發正在推動新療法的發展。主要參與者正在大力投資於非抗生素治療方案的研發。幾家製藥公司正在測試與抗生素化學相似的新型化合物。預計研發資金的增加將推動市場增長。例如，2021 年 11 月，PlateletBio 是一家臨床前階段的公司，投資於開發同種異體細胞治療的新方法，在 B 輪融資中籌集了 7550 萬美元，以推進該領域的開創性方法。該公司正在開發基於血小板生物學的新型同種異體細胞療法。該公司的主要候選人正在進行自身免疫性疾病免疫性血小板減少症（ ITP ）的臨床前開發。 2022年7月，處於臨床階段的生物技術公司Carmot Therapeutics, Inc.將加入旨在發現和開發代謝疾病和癌症疾病修飾療法的藥物發現平台Chemotype Evolution，宣布投資6000萬美元。

但是，長期使用抗生素可能會對患者產生不利影響並阻礙市場增長。然而，由於銅綠假單胞菌表現出耐藥性，資金有限的藥物研發公司紛紛退出市場。

內容

第一章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

• 按治療劃分的市場細分
• 按藥物類別劃分的市場細分
• 按管理途徑劃分的市場細分
• 按分銷渠道劃分的市場細分
• 按地區劃分的市場細分

第 4 章市場動態

• 市場影響因素
  • 驅動程序
    • 醫院獲得性感染 (HAI) 增加
    • 增加對銅綠假單胞菌藥物研發的投資
  • 限制因素
    • 銅綠假單胞菌的耐藥能力
• 商機
• 影響分析

第五章行業分析

• 波特五力分析
• 流行病學
• 管道分析
• 供應鏈分析
• 定價分析
• 監管分析
• 未滿足的需求
• COVID-19 影響分析

第 6 章治療

• 單一療法
• 聯合療法

第 7 章按藥物類別

• 氨基糖甘類
• 單巴坦系統
• 碳青黴烯類
• 頭孢菌素
• 其他

第 8 章給藥途徑

• 鼻腔
• 口語
• 靜脈給藥

第 9 章按分銷渠道

• 醫院藥房
• 零售藥房
• 在線藥店
• 其他

第 10 章按地區劃分

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第 11 章競爭格局

• 競爭場景
• 市場情況/份額分析
• 併購分析

第 12 章公司簡介

• Teva Pharmaceutical Industries Ltd.
  • 公司概況
  • 產品組合和描述
  • 主要亮點
  • 財務摘要
• AbbVie Inc.（Allergan plc）
• Pfizer, Inc.
• Merck & Co., Inc.
• AstraZeneca
• Bristol-Myers Squibb Co.
• Lupin Pharmaceuticals, Inc.
• Janssen Pharmaceuticals, Inc.
• Gilead Sciences Inc.
• Novartis AG（LIST NOT EXHAUSTIVE）

第13章 DataM

Market Overview

Pseudomonas aeruginosa infection treatment market was valued at USD 1.31 billion in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029).

Pseudomonas Aeruginosa (also known as P. aeruginosa) is an important cause of gram-negative infection, especially in patients with compromised host defense mechanisms. Pseudomonas aeruginosa is a multidrug-resistant pathogen known for its intrinsically advanced antibiotic resistance mechanisms, its antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections (HAIs) such as ventilator-associated pneumonia and various sepsis syndromes. These bacteria frequently cause urinary tract infections (UTIs), lung infections, pneumonia, and chronic pain. People with a low immune system are highly prone to affect by this infection.

The incidence of Hospital Acquired Infections (HAIs) has increased in recent years. As P. aeruginosa infection is one of the common infections in a hospital facility, the chances of being diagnosed with P. aeruginosa infection are high. This has led to an increase in research and development to find the treatment for P. aeruginosa. Several drugs are in the pipeline phases for the treatment of this infection.

Market Dynamics: rising incidences of nosocomial infections associated with P. aeruginosa

The pseudomonas aeruginosa infection treatment market growth is majorly driven by the rising incidences of nosocomial infections associated with P. aeruginosa, rapidly growing antibacterial resistance, and increasing research & development of pseudomonas aeruginosa infection treatments.

The rise in the prevalence of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others, are expected to drive the growth of the global pseudomonas aeruginosa infection treatment market over the forecast period. There is a rise in the incidence of pseudomonas aeruginosa infections in intensive care which is projected to boost the demand for newer pseudomonas aeruginosa infection treatment drugs. As per the Centers for Disease Control and Prevention (CDC), about 51,000 healthcare-associated pseudomonas aeruginosa infections occur in the United States annually. Over 6,000 (13%) of these are multidrug-resistant, with around 400 deaths per year attributed to these infections. The growing mortality rate owing to hospital-acquired infection(HAIs) is caused due to P. aeruginosa bacteria, especially in immunocompromised hosts. About 35 % of healthcare-acquired infections cause respiratory system infections, urinary infections, gastrointestinal infections, and other disorders, which leads to a rise in the demand for pseudomonas aeruginosa treatment.

In addition, increasing the usage of antibiotics for the treatment of pseudomonas aeruginosa infection is also driving market growth. Owing to the increasing use of antibiotics for the treatment of P. aeruginosa infection, the emergence of antibiotic-resistant bacterial strains has this line of treatment almost ineffective. In this scenario, pharma companies are focused on developing a treatment approach for the same. This provides ample white space for players in the pseudomonas aeruginosa infection treatment market to capitalize on.

The rising investments and extensive research & development are boosting the development of novel therapies. The major players are investing heavily in R&D for non-antibiotic treatment options. Several pharma companies are testing novel compounds that bear chemical similarities with antibiotics. Increasing funding for research and development is expected to boost market growth. For instance, in November 2021, PlateletBio, a preclinical stage company that invested in developing a new approach to allogeneic cell therapies, raised $75.5 million in a Series B financing round to advance its pioneering approach to the field. The company is developing new allogeneic cell therapies based on platelet biology. Its lead candidate is in preclinical development for immune thrombocytopenia (ITP), an autoimmune disease. Also, in July 2022, Carmot Therapeutics, Inc., a clinical-stage biotechnology company announced to invest 160 million USD financing for drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer.

However, extended use of antibiotics leads to harmful effects on the patient, which is likely to hamper the market growth. However, as P. aeruginosa shows the ability of drug resistance, several drug developers, who have limited funds are dissuaded from the market.

Market Segmentation: therapy segment for the highest share in global pseudomonas aeruginosa infection treatment market

The pseudomonas aeruginosa infection treatment market is classified by medication into monotherapy and combination therapy. Among these, the combination therapy segment accounted for the largest market share in the global pseudomonas aeruginosa infection treatment market in 2021. Combination therapy is used for the patient who has developed resistance property against monotherapy. During this therapy, a combination of different drugs is used to treat bacterial infections. The rise in drug resistance in monotherapy has increased the demand for combination therapy for the treatment of pseudomonas aeruginosa infection. As per the research, combination therapy showed promising results and the mortality was lower in patients receiving combination therapy, compared to monotherapy. Also, the growth of combination therapy for the treatment of P. aeruginosa infection is due to its rapid onset of action, high bioavailability rate, cost-saving, and high efficiency. Hence, these factors are expected to boost the growth of the combination therapy segment.

Based on drug class, the global pseudomonas aeruginosa infection treatment market is segmented into cephalosporin, aminoglycoside, carbapenem, monobactam, and others Among these, the cephalosporin segment held the largest market share in 2019, owing to the increasing development of a new class of cephalosporin for the treatment of various P. aeruginosa infections by significant companies. A new cephalosporin (fifth-generation) was developed for the treatment of gram-negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. The launch of a new cephalosporin class of drugs is likely to boost the growth of the segment.

Based on the route of administration, the global pseudomonas aeruginosa infection treatment market has been segmented into oral, nasal, and intravenous. The intravenous segment is expected to dominate the global pseudomonas aeruginosa infection treatment market during the forecast period because most of the drugs available for the intravenous route as it gives rapid onset of action and high accuracy in dosing compared with other routes. Most physicians prefer the intravenous route for the administration of drugs, as in the intravenous route, the entire dose reaches the systemic circulation immediately with rapid onset of action against bacteria.

Geographical Penetration: North America is the dominating region during the forecast period.

North America region is dominating the global pseudomonas aeruginosa infection treatment market accounted for the largest market share in 2021, owing to rising incidences of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others. As per the the Centers for Disease Control (CDC) estimates that HAIs account for an estimated 1.7 million infections and 99,000 associated deaths each year. In addition, 32 percent of all healthcare-acquired infection are urinary tract infections and 22 percent are surgical site infections. According to the Provincial Infection Control Network of British Columbia, HAIs are a major patient safety issue and economic burden for the healthcare system. In Canada, one in every nine hospital patients contracts a healthcare-associated infection. It is estimated that each year in Canada, there are more than 220,000 cases of HAI in Canada hospitals, resulting in at least 8,000 deaths. As Pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries. The U.S. and Canada have a well-developed health care system that encourages research and development for the treatment of these infections. These countries have a major presence of diverse global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Europe is the second-largest market for pseudomonas aeruginosa infection treatment in terms of market value, due to rising incidences of pseudomonas aeruginosa infection, the presence of major players, and the early adoption of new products. For instance, in Germany, about 22,000 to 33,000 people are suffering from pseudomonas aeruginosa infection.

The Asia-Pacific pseudomonas aeruginosa infection treatment market is expected to grow at the fastest growth rate over the forecast period. Developing countries such as China, India, and South Korea are expected to be lucrative markets over the forecast period, owing to growing awareness, increasing incidences of healthcare-associated pseudomonas aeruginosa infection, rapidly developing healthcare infrastructure, and high demand for advanced therapeutics. About 165,000 to 180,000 people in Australia suffer from hospital-acquired infections, as per a study, and of these, about 9,000 have pseudomonas aeruginosa infection.

Competitive Landscape:

The global players are manufacturing the majority of the pseudomonas aeruginosa infection treatment drugs and therapies. Some of the key players which are contributing to the growth of the market include AbbVie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Co., Lupin Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Gilead Sciences Inc., Novartis AG, among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the pseudomonas aeruginosa infection treatment market globally. For instance

In April 2021, CARB-X funded up to 5.3 million USD to Phico therapeutics to develop an engineered bacteriophage drug to treat ventilator-associated pneumonia caused by drug-resistant pseudomonas aeruginosa.

In May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., launched generic erythromycin tablets in the USA. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin. The tables are available in sizes of 250 mg and 500 mg.

In September 2019, Armata Pharmaceuticals, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients.

In March 2019, Allergan received the U.S. FDA approval for the AVYCAZ treatment of complicated intra-abdominal infections (cIAI) and urinary tract infections (cUTI) in pediatric patients.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Treatment
• 3.2. Market snippet by Drug Class
• 3.3. Market snippet by Route of Administration
• 3.4. Market Snippet by Distribution Channel
• 3.5. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Hospital Acquired Infections (HAIs)
    • 4.1.1.2. Growing Investment in Drug Discovery for Pseudomonas Aeruginosa
    • 4.1.1.3. XX
  • 4.1.2. Restraints:
    • 4.1.2.1. Drug Resistance Ability of Pseudomonas Aeruginosa
    • 4.1.2.2. XX
• 4.2. Opportunity
• 4.3. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology
• 5.3. Pipeline Analysis
• 5.4. Supply Chain Analysis
• 5.5. Pricing Analysis
• 5.6. Regulatory Analysis
• 5.7. Unmet Needs
• 5.8. COVID-19 Impact Analysis

6. By Treatment

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Segment
• 6.3. Market Attractiveness Index, By Treatment Segment
  • 6.3.1. Monotherapy*
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.3.2. Combination Therapy

7. By Drug Class

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
• 7.3. Market Attractiveness Index, By Drug Class Segment
  • 7.3.1. Aminoglycoside*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Monobactam
  • 7.3.3. Carbapenem
  • 7.3.4. Cephalosporin
  • 7.3.5. Others

8. By Route of Administration

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
• 8.3. Market Attractiveness Index, By Route of Administration Segment
  • 8.3.1. Nasal*
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Oral
  • 8.3.3. Intravenous

9. By Distribution Channel

• 9.1. Introduction
• 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
• 9.3. Market Attractiveness Index, By Distribution Channel Segment
  • 9.3.1. Hospital Pharmacies*
    • 9.3.1.1. Introduction
    • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
  • 9.3.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. Australia
    • 10.5.7.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Teva Pharmaceutical Industries Ltd.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. AbbVie Inc. (Allergan plc)
• 12.3. Pfizer, Inc.
• 12.4. Merck & Co., Inc.
• 12.5. AstraZeneca
• 12.6. Bristol-Myers Squibb Co.
• 12.7. Lupin Pharmaceuticals, Inc.
• 12.8. Janssen Pharmaceuticals, Inc.
• 12.9. Gilead Sciences Inc.
• 12.10. Novartis AG (LIST NOT EXHAUSTIVE)

13. DataM Intelligence

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us